cal02
Biologicalexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2016 (NCT02583373)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cal02
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05776004 | Phase 2 | Jul 22, 2023 | Eagle Pharmaceuticals, Inc. |
| NCT02583373 | Phase 1 | Mar 1, 2016 | Combioxin SA, University of Limoges |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Combioxin SA | For profit | 1 | 1 | 1 | 2016 |
| Eagle Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2023 |
| University of Limoges | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1